

Nothing less than another breakthrough in ED treatment

PiezoWave2 ED shows excellent results in a Randomized, Single-Blind, Sham-Controlled, Clinical Trial on 60 patients.

The research group led by Dr. Sramkova and Dr. Motil from the University of Prague and Brno is currently publishing a high level study on LSTC-ED. The publishing journal is Urologia Internationales, the international journal of the German Society of Urology. It must be considered a breakthrough that this journal has accepted and published the publication. It can be found online under the following link: <https://www.karger.com/Article/Abstract/504788>

Unfortunately, the study is not freely downloadable, but can be downloaded by paying a fee. We have ordered a limited number of offprints and will have them available in February at the latest.

Urologia
Internationales

Original Paper

Erectile Dysfunction Treatment Using Focused Linear Low-Intensity Extracorporeal Shockwaves: Single-Blind, Sham-Controlled, Randomized Clinical Trial

Sramkova T.^{a,b} · Motil J.^c · Jarkovsky J.^d · Sramkova K.^e

Abstract

Introduction: Low-intensity extracorporeal shock wave therapy (Li-ESWT) is a new treatment modality for erectile dysfunction (ED). Our aim was to evaluate the treatment outcome of Li-ESWT for ED in single-blind, placebo controlled, randomized clinical trial. **Methods:** Sixty patients were randomized into 2 age-matched groups: Group A – treatment and Group B – placebo. Treatment consisted of 4 sessions on the PiezoWave2 unit (R. Wolf and ELvation Medical). Effectiveness was assessed according to the International Index of Erectile Function 5 (IIEF-5), Erectile Hardness Score (EHS), questions 2 and 3 of the Sexual Encounter Profile (SEP 2, SEP 3), and Global Assessment Question (GAQ) scores at baseline and 4 and 12 weeks after treatment. We evaluated patient's and partner's subjective satisfaction. **Results:** A statistically significant difference between the groups was found at 4 and 12 weeks after treatment with regard to the quality of erection as measured by the IIEF-5 ($p = 0.049$ and $p < 0.001$, respectively), the EHS after week 12 ($p < 0.001$), an increase in the EHS after 4 and 12 weeks ($p = 0.030$ and $p < 0.001$, respectively), after 12 weeks in GAQ ($p < 0.001$), SEP 2 ($p = 0.05$), SEP 3 ($p < 0.001$), and patient's satisfaction ($p < 0.001$) and partner's satisfaction ($p < 0.001$). **Conclusions:** The randomized single-blind study confirms that Li-ESWT significantly improves erectile function.

© 2019 S. Karger AG, Basel



The randomized single-blind study confirms that Li-ESWT with PiezoWave2 significantly improves erectile function.... Our study showed positive effects of Li-ESWT in 66.7% of patients in the intervention group during week 12 of treatment.

